Celeste Manfredi1, Francesco P Calace2, Ferdinando Fusco1, Carmelo Quattrone1, Dario Giordano1, Felice Crocetto3, Massimiliano Creta3, Marco De Sio1, Davide Arcaniolo1. 1. Urology Unit, Department of Woman Child and of General and Specialist Surgery, University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, Italy. 2. Urology Unit, Department of Woman Child and of General and Specialist Surgery, University of Campania "Luigi Vanvitelli", Via S. Pansini 5, Naples, 80131, Italy. frap.calace@gmail.com. 3. Department of Urology, University "Federico II", Naples, Italy.
Abstract
PURPOSE: To evaluate the efficacy and safety of Escherichia coli Nissle 1917 (EcN) in association with levofloxacin in patients with chronic bacterial prostatitis (CBP). METHODS: Patients with CBP referred to our clinic from September 2017 to July 2019 were enrolled. At baseline, the symptomatology was assessed with the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), while the Meares-Stamey test was used to diagnose the infection. Patients were randomized (1:1) in two groups (A and B). All subjects underwent oral administration of Levoxacin® 500 mg once daily for 4 weeks. Only the patients in Group B underwent oral administration of EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks. After 3 months, each patient repeated the NIH-CPSI questionnaire, while the Meares-Stamey test was repeated at 3 and 6 months in patients who reported persistent symptoms. All adverse events (AEs) were recorded. RESULTS: A total of 110 patients were enrolled. After 3 months patients in Group B reported a significantly lower NIH-CPSI score (5.85 ± 3.07 vs. 7.64 ± 3.86; p = 0.009) and biological recurrences rate (9.8 vs. 26.9%; p = 0.043). At 6 months the biological recurrences rate was significantly lower in Group B (8.7 vs. 28.9%; p = 0.038). Only three patients in Group A and six in Group B (p = 0.25) complained mild AEs. CONCLUSIONS: Combination therapy with EcN and levofloxacin allows a better control of symptoms and biological recurrences in patients with CBP, without worsening the safety of the treatment.
PURPOSE: To evaluate the efficacy and safety of Escherichia coli Nissle 1917 (EcN) in association with levofloxacin in patients with chronic bacterial prostatitis (CBP). METHODS: Patients with CBP referred to our clinic from September 2017 to July 2019 were enrolled. At baseline, the symptomatology was assessed with the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), while the Meares-Stamey test was used to diagnose the infection. Patients were randomized (1:1) in two groups (A and B). All subjects underwent oral administration of Levoxacin® 500 mg once daily for 4 weeks. Only the patients in Group B underwent oral administration of EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks. After 3 months, each patient repeated the NIH-CPSI questionnaire, while the Meares-Stamey test was repeated at 3 and 6 months in patients who reported persistent symptoms. All adverse events (AEs) were recorded. RESULTS: A total of 110 patients were enrolled. After 3 months patients in Group B reported a significantly lower NIH-CPSI score (5.85 ± 3.07 vs. 7.64 ± 3.86; p = 0.009) and biological recurrences rate (9.8 vs. 26.9%; p = 0.043). At 6 months the biological recurrences rate was significantly lower in Group B (8.7 vs. 28.9%; p = 0.038). Only three patients in Group A and six in Group B (p = 0.25) complained mild AEs. CONCLUSIONS: Combination therapy with EcN and levofloxacin allows a better control of symptoms and biological recurrences in patients with CBP, without worsening the safety of the treatment.
Authors: Daniel A Shoskes; Jessica Altemus; Alan S Polackwich; Barbara Tucky; Hannah Wang; Charis Eng Journal: Urology Date: 2016-03-09 Impact factor: 2.649
Authors: T E Bjerklund Johansen; R N Grüneberg; J Guibert; A Hofstetter; B Lobel; K G Naber; J Palou Redorta; P J van Cangh Journal: Eur Urol Date: 1998-12 Impact factor: 20.096
Authors: Gian Maria Busetto; Riccardo Giovannone; Matteo Ferro; Stefano Tricarico; Francesco Del Giudice; Deliu Victor Matei; Ottavio De Cobelli; Vincenzo Gentile; Ettore De Berardinis Journal: BMC Urol Date: 2014-07-19 Impact factor: 2.264
Authors: Celeste Manfredi; Lorenzo Spirito; Francesco Paolo Calace; Raffaele Balsamo; Marco Terribile; Marco Stizzo; Lorenzo Romano; Luigi Napolitano; Gianluigi Califano; Luigi Cirillo; Giovanni Maria Fusco; Claudia Rosati; Carmelo Quattrone; Carmine Sciorio; Massimiliano Creta; Nicola Longo; Marco De Sio; Davide Arcaniolo Journal: Pathophysiology Date: 2022-07-13